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The liver is a central organ for homeostasis with unique regenerative capacities. Mature hepatocytes possess
a remarkable capacity to proliferate upon injury, challenging efforts to discern the role of adult liver stem cells
in this process. In contrast, stem/progenitor cells in the developing liver have been extensively characterized,
and these investigations have informed efforts to produce functional hepatocytes in vitro for cell therapy and
drug screening. In this Review, we describe recent advances in the characterization of liver stem cells and
discuss evidence supporting and refuting whether self-renewable and bipotential liver stem cells exist in
development, homeostasis, regeneration, and disease.Introduction
Stem cells are defined, in general, by their ability to self-renew
and differentiate into multiple lineages. Functionally, stem cell
activity can be defined by several methods. Clonogenicity and
multilineage differentiation in vitro are classical and convenient
assays to demonstrate stemness and have been widely used
to assess stem cell activity in various tissues. Genetic lineage
tracing and long-term label-retaining assays have been used to
identify and characterize stem cells in vivo. These assays have
allowed extensive characterization of several tissue-specific
stem cells, including intestinal stem cells, dermal stem cells,
and hair follicle stem cells (Barker et al., 2012; Blanpain and
Fuchs, 2009; Fuchs, 2009). Alternatively, long-term repopulation
upon transplantation of a single sorted cell has been long re-
garded as the gold standard of stem cell activity in the hemato-
poietic compartment (Oguro et al., 2013; Smith et al., 1991). The
stem cell for the liver has been defined as the cell that gives rise
to both hepatocytes and biliary epithelial cells (cholangiocytes),
the two types of liver epithelial cells. Although there are many re-
ports describing liver stem cells, the measures used to define
liver stem cells have not necessarily been adequate in many
cases. In this Review, we describe the defining characteristics
used to describe liver stem cells and discuss the evidence sup-
porting and refuting whether self-renewable and bipotential liver
stem cells exist in development, homeostasis, and regeneration.
Liver Functions and Architecture
The liver is a central organ for homeostasis and carries out awide
range of functions, including metabolism, glycogen storage,
drug detoxification, production of various serum proteins, and
bile secretion. Since liver functions are essential for homeosta-
sis, liver diseases, such as hepatitis, fibrosis, and cirrhosis, often
result in morbidity and mortality. The liver is unique in its extraor-
dinary capacity to regenerate from various injuries. Strikingly, the
liver’s ability to recover its original mass after surgical removal of
a significant portion makes it possible to transplant liver tissuefrom a living donor. The basic architectural unit of the liver is
the liver lobule, which is described in detail in Figure 1.
Most of the metabolic and synthetic functions of the liver are
carried out by hepatocytes, which account for approximately
60% of total liver cells and 80% of the volume of the organ.
Hepatocytes are highly polarized epithelial cells and form cords.
Their basolateral surfaces face fenestrated sinusoidal endothe-
lial cells, facilitating the exchange of materials between hepato-
cytes and blood vessels. Tight junctions formed between hepa-
tocytes create a canaliculus that surrounds each hepatocyte.
Bile secreted from mature hepatocytes is exported sequentially
through bile canaliculi surrounded by the apical membrane of
neighboring hepatocytes, intrahepatic bile ducts, extrahepatic
bile ducts, and, finally, the duodenum. The bile duct is formed
by a specialized type of epithelial cell called a cholangiocyte.
Hepatoblasts as the Liver Progenitor Cell in
Development
The onset of mouse liver development begins at embryonic day
(E) 8.5 from the foregut endoderm, which is derived from medial
and lateral domains of developing ventral foregut (Tremblay and
Zaret, 2005). The commitment of endoderm cells to the liver is
dictated by two crucial cytokines: fibroblast growth factor
(FGF) from the developing heart (Gualdi et al., 1996; Jung
et al., 1999) and bone morphogenetic protein (BMP) from the
septum transversum mesenchyme (STM) (Rossi et al., 2001).
The foregut endoderm cells destined for hepatic fate begin to
express transcription factors Hex and HNF4a as well as the
liver-specific genes a-fetoprotein (AFP) and albumin (ALB) and
migrate as cords into the surrounding STM. These cells are com-
mon progenitor cells, which give rise to both hepatocytes and
cholangiocytes, and are called ‘‘hepatoblasts’’ during liver
development. Historically, immunohistochemical analysis had
been used to characterize hepatoblasts; however, specific cell
surface markers for prospective isolation of hepatoblasts were
not identified until more recently. Because the fetal liver is aCell Stem Cell 14, May 1, 2014 ª2014 Elsevier Inc. 561
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Figure 1. Schematic Overview of Liver
Lobule
The portal triad consists of the portal vein,
hepatic artery, and bile ducts. Blood from the
portal vein and the hepatic artery flows toward
the central vein between hepatocytes through
the sinusoids surrounded by fenestrated hepatic
sinusoidal endothelial cells (HSECs). Bile pro-
duced by hepatocytes is collected into bile ducts
via the bile canaliculi. Kupffer cells, resident mac-
rophages of the liver, are located at the luminal
side of sinusoids, while hepatic stellate cells
(HSCs) are positioned in close proximity to HSECs
at the ‘‘space of Disse,’’ a location between
hepatocytes and a sinusoid. The canal of Hering
is the junctional region between hepatocytes and
bile ducts.
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of liver cells, a combination of negative selection by CD45 (com-
mon leukocyte antigen) and TER119 (erythroid cell antigen) and
positive selection by some cell surfacemarkers has been utilized
to successfully isolate hepatoblasts. In many cases, the sorted
cells from fetal liver were evaluated by the expression of liver-
specific genes such as AFP and ALB, clonogenicity and bipo-
tency in vitro, and their ability to repopulate adult liver upon
transplantation. Suzuki et al. (2000) developed a single-cell-
based assay called the hepatic colony-forming unit in culture
(H-CFU-C) and showed that the CD45– TER119– c-Kit– CD29+
CD49f+ fraction of E13.5 mouse liver contained colony-forming
cells with the potential to differentiate into hepatocytic and chol-
angiocytic lineages. Since then, sorting for c-Kitlow (Minguet
et al., 2003), c-Kit– c-Met+ CD49f+/low (Suzuki et al., 2003),
CD13+ (Kakinuma et al., 2009), or CD13+ c-Kit– CD49f/low
CD133+ (Kamiya et al., 2009) in combination with CD45 and
TER119 has been applied to isolate the hepatoblast compart-
ment. Alternatively, positive selection with a single specific
marker has also been reported to isolate hepatoblasts. Delta-
like 1 homolog (Dlk1), also known as Pref-1, is expressed in liver
buds as early as E9.0 in mouse embryo and can also be used
to isolate bipotential cells. Dlk1 expression is gradually
decreased in the liver by the neonatal stage and becomes unde-
tectable in adult liver. Dlk1+ cells isolated from E14.5 livers form
highly proliferative colonies composed of the hepatocyte and
cholangiocyte lineages in vitro (Tanimizu et al., 2003). E-cad-
herin, an epithelial-specific marker, was also utilized to isolate
hepatoblasts (Nitou et al., 2002; Nierhoff et al., 2005). E12.5 liver
epithelial cells were shown to specifically express E-cadherin,
Dlk1, and Liv2, a unique marker for epithelial cells in the E9.5–
E12.5 fetal liver (Watanabe et al., 2002), and sorted E-cadherin+
cells repopulated the liver after transplantation. Nierhoff et al.
(2007) also identified additional markers, CD24a and Neighbor
of Punc E11 (Nope), to isolate hepatoblasts by comparing the
gene expression profiles of purified E13.5 E-cadherin+ liver
cells and adult liver. Epithelial cell adhesion molecule (EpCAM)
was expressed in HNF4a+ hepatoblasts of liver buds as
early as E9.5 in mice. The EpCAM+ Dlk1+ cell population sorted
from E11.5 liver contained in vitro colony-forming cells, indi-
cating that hepatoblasts are present in this population at this562 Cell Stem Cell 14, May 1, 2014 ª2014 Elsevier Inc.early stage of liver development (Tanaka et al., 2009) (Figure 2).
However, clonogenic mouse hepatic cells were found in
EpCAM– Dlk1+ cells at E13.5, suggesting that hepatoblasts likely
change their characteristics during the course of liver develop-
ment. Alternatively, fate mapping by dye labeling revealed that
there are distinct endodermal regions that give rise to hepato-
blasts (Tremblay and Zaret, 2005), thus it might be possible
that regionally distinct hepatoblast descendants could have
different properties. Gadue et al. (2009) generated two mono-
clonal antibodies, ENDM1 and ENDM2, that show remarkable
specificity for mouse foregut ventral endoderm. Interestingly,
the endoderm population recognized by those antibodies has
the potential to generate cells of the hepatic lineage, although
these markers are downregulated by specification to the hepatic
fate. These antibodies may be useful to further study the charac-
teristics of endoderm progenitor cells (Xu et al., 2011). The
expression profile of representative cell surface markers during
liver development is illustrated in Figure 2, and the characteriza-
tion of hepatoblasts by prospective isolation is summarized in
Table 1.
Engraftment of in vitro expanded hepatoblasts in adult mouse
liver injury models can be used to demonstrate some aspects of
stem cell activity. However, unlike long-term repopulation of a
single sorted hematopoietic stem cell, which demonstrates
self-renewal and multidifferentiation potential in mice, engraft-
ment of hepatoblasts requires a large number of cells, with
more than 5 3 104 cells needed to engraft a single mouse or
rat (Kakinuma et al., 2009; Nierhoff et al., 2005; Oertel et al.,
2008; Suzuki et al., 2000; Tanimizu et al., 2003). In addition,
engraftment of transplanted hepatoblasts to bile ducts has
not necessarily been convincingly demonstrated, most likely
because of the lack of an appropriate bile duct injury model to
assess engraftment. Thus, transplantation studies using hepato-
blasts do not provide sufficient evidence to fulfill the stringent
criteria of ‘‘stemness’’ that is used for other stem cell types,
such as hematopoietic stem cells.
Stem Cell Properties of Fetal Liver Cells
Several reports using culture systems have demonstrated the
presence of a potential liver ‘‘stem cell’’ in the fetal liver, which
has the capacity for unlimited proliferation and multilineage
Figure 2. Schematic Model of Regulatory
Mechanisms and Cell Surface Markers for
Hepatic Epithelial Cells during Mouse Liver
Development
The representative cell surface markers are shown.
While EpCAM is transiently downregulated in hep-
atoblasts at themidgestational stage, its expression
is restored in cholangiocytes, but not in hepato-
cytes, later on. DLK1 is also expressed in hepato-
blasts but is not expressed inmature hepatocytes or
cholangiocytes.
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cells named ‘‘HPPL’’ that continuously proliferate on laminin-
coated plates and differentiate to both hepatocytes and cholan-
giocytes under differentiation conditions (Tanimizu et al., 2004).
Similar bipotential cell lines exhibiting the properties of liver
stem cells were also obtained after a long latency period in cul-
ture of fetal liver cells, though their specific cellular origin was
unknown (Strick-Marchand and Weiss, 2002; Tsuchiya et al.,
2005). One of the cell lines, referred to as BMEL (Strick-
Marchand and Weiss, 2002), expresses hepatocytic transcrip-
tion factors such as HNF1a, HNF4a, and GATA4, but not ALB.
Because BMEL cell lines can be generated reproducibly, the
bipotential progenitors provide a useful experimental model to
study the mechanism of differentiation.
Dan et al. (2006) established cells similar to those mouse
cells—multipotent progenitor cells from human fetal liver cells
in long-term culture named ‘‘hFLMPCs,’’ which exhibited capac-
ities of self-renewal, multipotent differentiation, and repopulation
in a mouse liver injury model. Intriguingly, the hFLMPCs ex-
pressed several stem-cell-related markers, such as CD90,
c-Kit, CD44h, and EpCAM, but neither AFP nor ALB. Schmelzer
et al. (2007) reported that EpCAM+ cells isolated from human
fetal liver contained multipotent precursors of hepatoblasts,
which expressed stem cell markers and could be expanded in
culture. The cultured EpCAM+ cells, which they called hepatic
stem cells (hHpSCs), expressed ALB weakly, but no AFP. Trans-
plantation of freshly isolated EpCAM+ cells or hHpSCs expanded
in culture into NOD/SCID mice resulted in mature liver tissue ex-
pressing human-specific proteins. Recently, Goldman et al.
(2013) reported that mouse and human fetal liver cells distinct
from endothelial cells expressed KDR, also known as VEGFR2/
Flk1, and expressed low levels of ALB. A lineage-tracing exper-
iment using the Kdr-Cre mouse revealed that KDR+ cells were
present in the endoderm in E8.0 embryos prior to hepatic spec-
ification and that the labeled hepatic progenitor gave rise to
hepatocytes and cholangiocytes, suggesting that KDR+ ALB
AFP hepatic progenitors are a precursor of hepatoblasts
(Figure 2). Ultimately, the absence of liver-specific ALB or AFP
in ‘‘fetal liver-derived stem-like cells’’ expanded in vitro suggests
that fetal liver stem cells may be present as hepatoblast precur-
sors, such as foregut endoderm stem cells, rather than hepato-Cell Stem Cblasts in vivo. In other words, if the liver
stem cell were defined as a persistently
self-renewable cell, most hepatoblasts
would be unlikely to fall into this category.
Because liver development from foregut
endoderm is a continuous process, itseems likely that the cell surface characteristics of hepatoblasts
change over time. Whether or not fetal liver cells with self-
renewal capacity persist throughout an individual’s life span
remains an open question.
Mechanisms Underlying the Proliferation and
Differentiation of Hepatoblasts
Proliferation and differentiation of hepatoblasts are supported
and coordinated by various cell types in the liver during embryo-
genesis. Here, we focus on the cell-to-cell interactions relevant
to the growth and differentiation of hepatoblasts into hepato-
cytes (Figure 2). At the earliest stage of liver development, hep-
atoblasts emerge from foregut endoderm and proliferate to form
the liver bud in a process that requires Flk1+ endothelial cells in
STM (Matsumoto et al., 2001). At later stages, mesothelial cells
(MCs), which form the mesothelium that covers the parenchyma
and prevents adhesion with other tissues, express high levels of
various growth factors for hepatocytes such as HGF, Midkine,
and Pleiotrophin (Onitsuka et al., 2010). Fetal MCs enhance
proliferation of Dlk1+ hepatoblasts/immature hepatocytes in a
coculture system. Wilms tumor 1 (WT1) is a transcription factor
essential for development of MCs and the lack of WT1 impairs
liver growth (Ijpenberg et al., 2007). Together, these results indi-
cate that immature MCs contribute to hepatoblast proliferation.
By contrast, Thy1+ mesenchymal cells in the murine fetal liver
promote the maturation of CD49f+ hepatic progenitor cells by
direct cell-to-cell contact in a coculture system (Hoppo et al.,
2004). Interestingly, human embryonic stem cell (ESC)-derived
KDR+ AFP hepatic progenitors were shown to promote the
maturation of KDR AFP+ hepatic cells in vitro, suggesting the
possibility that a small population of hepatoblasts itself provides
a niche for hepatic maturation (Goldman et al., 2013). Hemato-
poietic cells start to colonize the liver in midgestation, and the
fetal liver serves as the major hematopoietic tissue until the
perinatal stage when hematopoiesis shifts to the bone marrow.
Hepatoblasts/immature hepatocytes are closely associated
with hematopoietic precursor cells and support hematopoiesis
in fetal liver. Reciprocally, cytokines secreted from blood cells
play a pivotal role for functional and morphological maturation
of hepatocytes; e.g., Oncostatin M (OSM), an interleukin-6 family
member, produced by hematopoietic cells promotes hepatocyteell 14, May 1, 2014 ª2014 Elsevier Inc. 563
Table 1. Identification of Hepatoblasts by Cell Sorting Using Cell Surface Markers
Species
Developmental
Stage Used for
Assays
Used Markers for
Cell Sorting
Afp or Alb
Expression Clonogenicity
Bipotency in
Clonogenic
Analysis
Repopulating
Activity In Vivo References
Mouse E13.5 CD45/TER119–/c-Kit–/
CD29+/CD49f+
+ + + + (Suzuki et al., 2000)
E12.5 E-cad+ + NT hepatocytic NT (Nitou et al., 2002)
E11 CD45–/TER119–/c-Kitlow + + + chimeric fetal liver
organoids
(Minguet et al., 2003)
E14.5 Dlk1+ + + + + (Tanimizu et al., 2003)
E13.5 CD45–/TER119–/c-Kit–/
c-Met+/CD49f+/low
+ + + NT (Suzuki et al., 2003)
E12.5 E-cad+, Liv2+ + + NT + (Nierhoff et al., 2005)
E13.5 Nope+, CD24a+ + NT NT NT (Nierhoff et al., 2007)
E11.5 Epcam+/Dlk1+ + + NT NT (Tanaka et al., 2009)
E13.5 CD45–/TER119–/CD13+ + + + + (Kakinuma et al., 2009)
E13.5 CD45/TER119/c-Kit/
CD13+/CD49f/low/CD133+
+ + + NT (Kamiya et al., 2009)
Rat E13 RT1AlOX18low/ICAM-1+ + + + NT (Kubota and Reid, 2000)
E16–E18 (OX43/OX44)–/Thy-1+ + NT NT NT (Fiegel et al., 2003)
E14 Dlk-1+ + NT + + (Oertel et al., 2008)
Human 18–22 week
gestation age
EpCAM+ + + + + (NOD/SCID mice) (Schmelzer et al., 2007)
NT, not tested.
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bolic enzymes and the formation of adherens junctions (Kamiya
et al., 1999, 2002; Matsui et al., 2002). Hematopoiesis shifts
from fetal liver to the bone marrow around birth, and metabolic
and synthetic functions of the liver drastically change as reflected
by the altered expression of various genes. Typically, xenobiotic-
metabolizing cytochrome P450 genes are highly upregulated in
neonatal stages. However, the metabolic shift is not a uniform
process. Even fully mature hepatocytes constitute heterogenous
cell populations depending on their location within a hepatic
lobule, which is referred to as ‘‘metabolic zonation.’’ A number
of genes related to metabolism are differentially expressed in
either the periportal or pericentral zone. Despite several studies
investigating the involvement ofWnt/b-catenin signaling inmeta-
bolic zonation (Benhamouche et al., 2006; Burke et al., 2009;
Sekine et al., 2006), the responsible Wnt ligand remains unclear.
Mechanisms Regulating the Differentiation of
Hepatoblasts into Cholangiocytes
In contrast to hepatocyte maturation, bile ducts are formed spe-
cifically around the portal vein, indicating that there must be a
regionally specific cue for the induction of cholangiocytes from
hepatoblasts. Although intrahepatic bile ducts are not visible
by E16 in mouse liver, the specification of cholangiocyte lineage
from hepatoblasts occurs around E15 in the vicinity of portal vein
branches. Alagille syndrome is a human autosomal-dominant
developmental disorder that is characterized by defects in mul-
tiple organs including impaired differentiation of intrahepatic
bile ducts. NOTCH2 and JAGGED1, a ligand for Notch family re-
ceptors, have been identified as the genes that cause this disor-
der (Alagille et al., 1987; Li et al., 1997; McDaniell et al., 2006;564 Cell Stem Cell 14, May 1, 2014 ª2014 Elsevier Inc.Oda et al., 1997). Consistently, Notch2 is expressed in hepato-
blasts, whereas Jagged1 is expressed in periportal mesen-
chymal cells (Kodama et al., 2004), and a mouse model with
the double mutations of Notch2 and Jagged1 exhibited the
paucity of intrahepatic bile ducts that is observed in humans
(McCright et al., 2002). Activation and/or inactivation of Notch
signaling in vivo and in vitro have demonstrated that biliary
duct mophogenesis and/or differentiation are affected by Notch
signaling in the periportal region (Hofmann et al., 2010; Tanimizu
and Miyajima, 2004; Zong et al., 2009). These results indicate
that Notch signaling plays a critical role for bile duct develop-
ment. Another important signaling pathway regulating biliary
differentiation is TGF-b/Activin. TGF-b2 and TGF-b3 are pre-
dominantly expressed in the portal region (Antoniou et al.,
2009), and HNF6 (OC-1) and OC-2, onecut transcription factors
controlling biliary tract development, modulate expression of
a2-macroglobulin and follistatin, which are inhibitors of the
TGF-b/Activin pathway, in the parenchymal region (Clotman
et al., 2005). Collectively these studies revealed that various
types of fetal liver cells constitute the niche for proliferation
and differentiation of hepatoblasts (Figure 2).
Programming and Reprogramming Hepatic
Development In Vitro
Reproduction of liver development from embryonic stem cells
(ESCs) or induced pluripotent stem cells (iPSCs) in vitro provides
a proof of principle for liver organogenesis and also paves the
way for practical use of hepatocytes in drug screening and trans-
plantation settings. Liver transplantation is the only established
effective treatment for end-stage liver diseases; however, a
shortage of donors limits this treatment. As alternatives to organ
Cell Stem Cell
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bioartificial livers with functional hepatocytes may provide
potentially effective treatments. For such practical uses, a large
quantity of hepatocytes will be needed and accordingly, efforts
have been made toward generating hepatocytes from pluripo-
tent stem cells (PSCs). Because freshly isolated hepatocytes
from adult liver rapidly lose their function in culture, generation
of fully functional hepatocytes from PSCs in vitro is a difficult
task. Nevertheless, progress has been made toward this goal
based on our understanding of liver development. By recapitu-
lating developmental processes, step-wise protocols to differen-
tiate hepatocytes from PSCs have been established. Typically,
PSCs are induced to become definitive endoderm with Activin
A in a monolayer culture, BMP4 and FGF2 are added to induce
hepatic specification, HGF to induce differentiation into imma-
ture hepatocytes, and OSM with or without dexamethasone
(Dex) to generate mature hepatocytes (Si-Tayeb et al., 2010).
Aggregation culture of human ESC (hESC)-derived hepatocytes
together with cAMP further enhanced maturation (Ogawa et al.,
2013). While there is still room for improvement in terms of matu-
ration, human iPSCs (hiPSCs) can be used formodeling inherited
diseases. Rashid et al. (2010) generated iPSCs from patients
with a1-anti-trypsin deficiency, familial hypercholesterolemia,
and glycogen storage disease and showed that hepatocytes
derived from patient-derived iPSCs recapitulate pathological
features of the diseases. Furthermore, targeted gene correction
of a1-anti-trypsin deficiency in iPSCs restored structure and
function of a1-anti-trypsin in iPSC-derived hepatocytes (Yusa
et al., 2011).
During the course of the differentiation process from PSCs,
hepatoblasts with the potential to differentiate to both hepato-
cytes and cholangiocytes are expected to emerge. Accordingly,
hepatoblast-like cells expressing both hepatocyte and cholan-
giocyte markers were shown to emerge from PSCs, and they
were able to differentiate to hepatocytes and form cysts of chol-
angiocytes in vitro (Yanagida et al., 2013; Zhao et al., 2009). The
liver progenitors were expanded on stromal cells in vitro, and
transplantation into mouse liver injury models, such as fumaryla-
cetoacetate-hydrolase (Fah) deficiency, allowed engraftment
and subsequent differentiation to hepatocytes. In other proto-
cols, by transient adenoviral-induced expression of Hex, a
homeotic gene essential for hepatic differentiation, PSC-derived
liver progenitors were generated (Takayama et al., 2013). The
Hex-induced cells proliferated and maintained the potential for
bidirectional differentiation in vitro and were capable of engraft-
ment in a CCl4-injured liver. Recently, induced multipotent
progenitor cells (iMPCs), which were generated from partially re-
programmed human fibroblasts, were shown to differentiate to
hepatocytes (Zhu et al., 2014). A similar approach has also
been recently used to generate endoderm-like cells capable of
differentiating into pancreatic lineages (Li et al., 2014). Impor-
tantly, iMPC-derived endoderm progenitors proliferated exten-
sively, and their differentiation was induced with both small
molecules that are known to promote hepatocyte differentiation
from PSCs and inhibitors against TGF-b and Notch signaling
pathways that are known to promote biliary differentiation,
resulting in more differentiated hepatocyte phenotypes as
compared to iPSC-derived hepatocytes. Nonetheless, iMPC-
hepatocytes more closely resembled human fetal hepatocytes.Upon transplantation, iMPC-hepatocytes proliferated exten-
sively in an immunodeficient Fah/ mouse; however, human
serum albumin was not detected for 2 months, indicating that
the transplanted cells are still immature and require a substantial
maturation period in mouse.
Because the development and differentiation of hepatocytes
are supported by various nonparenchymal cells such as endo-
thelial cells and mesenchymal cells, it is likely that addition of
those cells to differentiation culture of hepatocytes from ESCs/
iPSCs would improve hepatic functions. Recently, Takebe
et al. (2013) developed a coculture system of human iPSC-
derived hepatic specified definitive endoderm with human
umbilical vein endothelial cells (HUVECs) and mesenchymal
cells, in which 3D cell clusters are formed. Hepatocytes in the
cell clusters expressed many hepatic enzymes. Upon transplan-
tation of the cell clusters into mice, they became vascularized
and expressed liver proteins, resulting in improved survival of
mice in a toxin injury model. These characteristics suggest that
the cell clusters developed in vitro may be considered as liver
organoids. However, the cells do not reconstitute the full liver
or exhibit long-term function, and their differentiation to cholan-
giocytes as well as their formation of biliary architecture remains
to be demonstrated. Goldman et al. (2013) recently reported an
intriguing observation that hESC-derived endoderm cells do not
express KDR, but generate KDR+ hepatic progenitors and KDR
hepatic cells when cultured inmedia supporting hepatic differen-
tiation. KDR+ progenitors are supportive cells for the maturation
of committed hepatic cells and hepatic cells generated from
KDR+ progenitors support HCV infection. Taken together, these
studies demonstrate the benefits of including supporting cells in
PSC-derived hepatocyte culture.
Hepatocyte-like cells were also derived from cells of nonhe-
patic lineages, such as human mesenchymal cells in bone
marrow or CD105+ mesenchymal cells in adipose tissue, by
being incubated with FGF and HGF and then OSM and Dex
(Banas et al., 2007; Lee et al., 2004). More recently, mouse fibro-
blasts were directly reprogrammed by combined expression
of transcription factors, including Hnf4a plus Foxa1, Foxa2, or
Foxa3 (Sekiya and Suzuki, 2011), and Gata4, Hnf1a, and
Foxa3 together with inactivation of p19Arf (Huang et al., 2011).
Those reprogrammed cells, called iHep cells, closely resemble
hepatocytes and express hepatic genes. Notably, transplanted
iHep cells repopulated the livers of Fah/ mice and rescued
the lethal phenotype. Importantly, human fibroblasts can also
be directly reprogrammed to hepatocytes that exhibit key meta-
bolic functions by expression of FOXA3, HNF1A, and HNF4A
(Huang et al., 2014) or a combination of HNF1A, HNF4A, and
HNF6 together with the maturation factors ATF1, PROX1, and
CEBPA (Du et al., 2014). It is notable that different sets of
transcription factors can reprogram fibroblasts to hepatocytes.
This plasticity is quite reminiscent of the flexible and self-sustain-
ing cross-regulatory network that operates during liver organo-
genesis (Kyrmizi et al., 2006), whose incipient activation by any
of the sets of reprogramming factors could be sufficient to ignite
the self-organizing developmental program to achieve function-
ally differentiated hepatocytes. Alternatively, it could reflect
some difference in fibroblasts and/or culture conditions used
for reprogramming. The characteristics of the reprogrammed
hepatocytes may not necessarily be the same among theseCell Stem Cell 14, May 1, 2014 ª2014 Elsevier Inc. 565
Figure 3. Stem/Progenitor Cells in Adult
Liver under Normal and Injured Conditions
Under normal physiological conditions, homeo-
static maintenance of hepatocytes is achieved
predominantly by proliferation of mature hepato-
cytes. Upon certain types of injury condition,
unique epithelial cell populations with an immature
phenotype, called adult liver progenitor cells (LPCs),
emerge and expand, and are thought to contribute
to the regeneration process due to their bilineage
differentiation potential to both hepatocytes and
cholangiocytes. Although the origin of LPCs is still
not clear, the dominant theory is that they are
derived from the canal of Hering, which may harbor
putative ‘‘resident’’ stem cells as the exact cell of
origin. Purification by cell sorting and subsequent
culture experiments have demonstrated that the
cholangiocyte marker-positive population from
normal liver, as well as the cholangiocyte/LPC
marker-positive subset from injured liver, contains
a ‘‘potential’’ liver stem cell population defined
in vitro by clonogenicity and bilinegae differentiation
potential.
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mechanisms should lead to improvement in reprogramming
strategies. The direct reprogramming strategy has also been
used to successfully produce hepatoblast-like cells, called
induced hepatic stem cells (iHepSCs), from mouse embryonic
fibroblasts by introducing Hnf1b and Foxa3 (Yu et al., 2013).
iHepSCs are capable of showing bilineage differentiation
in vitro as well as in vivo, and they may potentially offer an
expandable source for production of functional hepatocytes.
While these efforts to generate functional hepatocytes or
progenitor cells from pluripotent/multipotent stem cells or by
reprogramming somatic cells are encouraging, practical use of
the cells will require a more sophisticated understanding of their
terminal differentiation.
Stem Cells in the Normal Adult Liver
Although careful consideration is required as to whether hepato-
blasts can truly be called ‘‘stem cells’’ in the fetal liver as
mentioned earlier, they nevertheless can be regarded as a
bona fide progenitor cell population with bilineage differentiation
potential in vivo. The situation regarding stem/progenitor cells,
however, is further complicated in the adult liver. The nature
and role of tissue stem cells in adult organs/tissues can be
considered, for simplicity, in the context of two distinct (though
closely related) processes; namely, homeostatic maintenance
(or tissue turnover) under normal physiological conditions, and
tissue repair/regeneration under pathological conditions upon
various types of injury. In many tissues/organs, such as the
hematopoietic system, intestine, and epidermis,mature differen-
tiated cells have a short life span and their continuous replenish-
ment from the stem cell compartment is critical to maintain
structural and functional integrity of the tissue/organ. In contrast,
the normal turnover of mature hepatocytes slowly occurs over a
period of more than several months (MacDonald, 1961; Magami566 Cell Stem Cell 14, May 1, 2014 ª2014 Elsevier Inc.et al., 2002), and it is therefore question-
able whether any stem cell is required for
liver maintenance, at least under normal
conditions. As such, a widely acceptedview in the field argues that maintenance of hepatic tissue under
normal physiological conditions is achieved by proliferation of
mature hepatocytes that occurs throughout the liver paren-
chyma (Figure 3).
The slow turnover rate of hepatocytesmakes it practically diffi-
cult to apply the long-term label-retaining assay to identify stem
cells in vivo in the adult liver. Instead, many recent studies have
employed Cre/loxP-mediated genetic marking and lineage
tracing systems to characterize the mode of tissue maintenance
in the adult mouse liver. A long-lasting, yet still inconclusive,
model for hepatocyte turnover is the so-called ‘‘streaming liver
hypothesis.’’ Based on radiolabeled nucleotide-incorporation
assays in the rat liver, Zajicek et al. (1985) claimed that new pro-
duced hepatocytes appear in the periportal area (where bile
ducts exist) and flow along the hepatic cord toward the pericen-
tral region to continuously replenish the tissue, thus implying the
existence of a possible stem cell compartment for homeostatic
maintenance of the adult liver. Since then, much evidence has
accumulated both in favor and against this hypothesis. The
most powerful, and rather surprising, evidence supporting this
theory was provided by a genetic lineage tracing study based
on the cholangiocyte marker Sox9 (Furuyama et al., 2011). Using
a knockin (KI) mouse strain where the inducible recombinase
CreERT2 is inserted into the Sox9 locus, cholangiocytes, but
not hepatocytes, were lineage-labeled in the normal adult liver.
The label gradually spread out to hepatocytes from the periportal
toward pericentral regions and eventually occupied nearly the
whole parenchyma after 1 year. The labeled cells also remained
present in bile ducts, indicating that the Sox9-expressing chol-
angiocytes can continuously supply mature hepatocytes for
normal tissue turnover while possessing self-renewing activity
as well.
However, subsequent studies by other groups employing
different types of genetic lineage tracing systems have together
Table 2. Identification and Characterization of Adult Liver Stem/Progenitor Cells by Cell Sorting
Species
Markers and/or the
Mouse Lineage Tracing
Model Used
Liver Sample/Disease
Model Used Clonogenicity
Bipotency in
Clonogenic
Analysis
Repopulating
Activity In Vivo References
Mouse CD133+/CD45 normal + + NT (Rountree et al., 2007)
ANIT + + NT (Rountree et al., 2007)
CCl4 (chronic) + + NT (Rountree et al., 2007)
DDC + + NT (Rountree et al., 2007)
CD133+/D45/ TER119 normal ± (small colonies only) cholangiocytic NT (Suzuki et al., 2008)
DDC + (both large and
small colonies)
+ + (Fah/ mice) (Suzuki et al., 2008)
CD45/TER119/c-Kit/
Sca1/CD13+/CD49f+/
CD133+
normal + + + (nude mice,
Rs + PHx)
(Kamiya et al., 2009)
Epcam+ normal + + NT (Okabe et al., 2009)
DDC + + NT (Okabe et al., 2009)
CD24+/CD45/TER119 normal NT NT + (Fah/ mice) (Qiu et al., 2011)
MIC1-1C3+/CD133+/
CD26/CD45/CD11b/
CD31
normal + + ± (Fah/ mice) *1 (Dorrell et al., 2011)
DDC + + ± (Fah/ mice) *1 (Dorrell et al., 2011)
Sox9-CreERT2 BAC Tg
(R26R-YFP reporter+)/
CD45/CD11b/CD31
DDC + NT NT (Dorrell et al., 2011)
Foxl1-Cre Tg (R26R-YFP
reporter+)/CD45
DDC + + NT (Shin et al., 2011)
Lgr5-LacZ KI (LacZ+) CCl4 (acute) + (organoids) + + (FRG mice) (Huch et al., 2013)
Rat EpCAM+ D-gal NT NT + (Rs + PHx) (Yovchev et al., 2008)
Human EpCAM+ neonates (0–1 year);
pediatric (2–13 years);
adult (19–81 years)
+ + + (NOD/SCID
mice)
(Schmelzer et al., 2007)
ALDH+ (enzyme activity) (unknown) + hepatocytic NT (Dolle´ et al., 2012)
NT, not tested. ANIT, a-naphthylisothiocyanate; DDC, 3,5-diethoxycarbonyl-1,4-dihidro-collidine; D-gal, D-galactosamine. Rs + PHx, retrorsine +
partial hepatectomy; FRG, Fah/ Rag2/ Il2rg/. *1 < 0.1% of the total liver in 2 out of 20 Fah/ mice (Huch et al., 2013).
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using a different Sox9-CreERT2 strain (BAC transgenic) (Car-
pentier et al., 2011) or osteopontin (OPN)-CreERT2 (Espan˜ol-
Sun˜er et al., 2012) to label cholangiocytes did not observe the
flow of lineage-labeled cells out of the bile duct. Meanwhile, in
studies using a complimentary approach where hepatocytes
were initially labeled by a Cre-expressing adeno-associated viral
(AAV) vector, contribution of label-negative, nonhepatocytic line-
age cells (including cholangiocytes) for the maintenance of
parenchymal tissue was not observed (Malato et al., 2011;
Yanger et al., 2013). Overall, the results strongly argue against
the streaming liver hypothesis, although they do not completely
refute the possibility that the cell of origin for the ‘‘stream’’ still ex-
ists among periportal hepatocytes, rather than cholangiocytes.
Given that cholangiocytes are indeed capable of contributing
to parenchymal regeneration under certain types of liver injury
conditions, even in the OPN-CreERT2 system (Espan˜ol-Sun˜er
et al., 2012), it seems likely that cholangiocytes in the Sox9-
CreERT2 KI mouse liver (Furuyama et al., 2011) are somehow
biased to differentiate to hepatocytes due to genetic and/or
environmental factors, the natures of which are of potential
interest. Further studies are needed to resolve this discrepancyand elucidate the exact mode and the underlying mechanisms
for physiological maintenance of the liver.
Notably, another study by Iverson et al. (2011) used a unique
‘‘in vivo chronometer’’ system based on Alb-Cre-mediated fluo-
rescent color conversion. The result suggested that 0.076%of all
hepatocytes in steady-state adult mouse liver were newly born
within the previous 4 days from Alb-Cre cell populations, which
could potentially contribute to homeostatic maintenance of liver
parenchyma under normal conditions. Because the Alb-Cre
activity is induced in hepatoblasts at the fetal stage and con-
tinues during their maturation to adult hepatocytes, this result
implicates a contribution of nonepithelial lineage cells for hepa-
tocyte maintenance, an intriguing possibility that needs to be
further evaluated in other experimental settings.
Notwithstanding this complicated situation regarding in vivo
identification, many groups have succeeded in isolating ‘‘liver
stem cell’’ populations from the adult liver based on marker
gene expression and flow cytometric cell purification followed
by in vitro cultivation (Table 2 and Figure 3). As is the case with
the fetal liver cells, the cells in question can be defined as
‘‘stem cells’’ because they are (1) clonogenic with high growth
potential, (2) able to inducibly differentiate to both hepatocyteCell Stem Cell 14, May 1, 2014 ª2014 Elsevier Inc. 567
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tions, and, in some cases, (3) capable of repopulating the liver
upon transplantation. Although these cells can be considered
as ‘‘potential’’ liver stem cells because they can be functionally
defined in culture, it remains unclear whether and where they
exist in situ in living organisms and how they behave under phys-
iological conditions. It should be noted that potential liver stem
cell populations are usually identified as those that are positive
for cholangiocyte markers including EpCAM (Okabe et al.,
2009), CD133 (also known as prominin 1) (Kamiya et al., 2009),
and the MIC1-1C3 antigen (Dorrell et al., 2011), implicating a
possible role of the biliary system as a compartment harboring
‘‘resident’’ liver stem cells, if they exist (Figure 3). In support of
this theory, EpCAM+ cells isolated from postnatal human livers,
as well as from fetal livers as mentioned earlier, have also been
found to contain hepatic stem cells (hHpSCs) that can be defined
based on their in vitro function (Schmelzer et al., 2007). More-
over, multipotential stem/progenitor cells that can give rise to
hepatocytes, cholangiocytes, and pancreatic islets have been
identified in humans within the peribiliary glands, which are
unique epithelial structures in the extrahepatic biliary tree (Cardi-
nale et al., 2011; Carpino et al., 2012). The corresponding stem/
progenitor cells with similar characteristics and anatomical local-
ization may also be present in mice (Dipaola et al., 2013; Irie
et al., 2007), although they have not been fully characterized.
Stem/Progenitor Cells in Liver Regeneration
The characteristic feature of the liver is its high regenerative
capacity, and there has also been debate, with some skepticism,
as to whether stem cells are involved in this process. This skep-
ticism is primarily because partial hepatectomy (PHx), the surgi-
cal removal of (a) particular lobe(s) of the organ, has long been
regarded as the paradigm for experimental analysis of themech-
anisms underlying liver regeneration (Michalopoulos, 2007;
Michalopoulos and DeFrances, 1997). The PHx protocol does
not cause any injury to the remnant hepatic tissue, and the sub-
sequent regenerative process is considered to be achieved by
hypertrophy and proliferation of mature hepatocytes (Miyaoka
et al., 2012), without apparent involvement of any immature
stem cell population. Indeed, the results of recent genetic line-
age tracing studies in mice support this notion (Espan˜ol-Sun˜er
et al., 2012), although a small yet significant proportion of
newborn hepatocytes generated from cellular sources other
than preexisting hepatocytes has also been suggested (Fur-
uyama et al., 2011; Iverson et al., 2011; Malato et al., 2011).
Nevertheless, the robust regenerative capacity of hepatocytes
manifested upon PHx is quite striking and thus might have
contributed to a widespread prejudice that the liver does not
require any stem/progenitor cells for its regeneration.
While PHx is truly an excellent model to study the process of
compensatory growth of the liver and provides useful informa-
tion relevant to living donor liver transplantation, it does not faith-
fully recapitulate pathological situations in many human liver
diseases, which often involve hepatocyte death and concomi-
tant induction of inflammatory and fibrogenic responses. Under
many pathological conditions, such as chronic viral hepatitis,
alcoholic liver disease, and nonalcoholic fatty liver disease,
unique epithelial cell populations emerge and expand that are
not usually observed in a normal liver (Figure 3). These cells typi-568 Cell Stem Cell 14, May 1, 2014 ª2014 Elsevier Inc.cally exhibit immature and intermediate phenotypes between
hepatocytes and cholangiocytes as determined by morphology
and molecular marker expression, and they are considered
to be bipotential progenitor cell populations (Fausto, 2004;
Roskams et al., 2003, 2004; Tura´nyi et al., 2010). Such cell pop-
ulations have been termed in several different ways, such as
‘‘ductular hepatocytes,’’ ‘‘atypical ductal cells,’’ ‘‘intermediate
hepatobiliary cells,’’ or ‘‘hepatic/liver progenitor cells (HPCs/
LPCs).’’ The term ‘‘oval cells,’’ which was originally coined to
describe a specific, ovoid cell population observed in a rat model
of liver carcinogenesis (Farber, 1956), is also often used, partic-
ularly in rodent models. Some researchers consider such dis-
ease-activated progenitor cell populations as ‘‘liver stem cells’’
and, indeed, the term ‘‘oval cells’’ is sometimes introduced in
literature as a synonym for liver stem cells.
Oval cells are the prototype for adult liver stem/progenitor cell
populations, which emerge when the liver is injured under condi-
tions causing defective hepatocyte proliferation (Fausto, 2004).
The most established and reliable protocol currently used to
induce oval cells is the 2-acetylaminofluorene (2-AAF)/PHx sys-
tem in rats, where hepatocyte proliferation is blocked by 2-AAF
prior to application of PHx (Evarts et al., 1987). Ever since their
first description by Farber in 1956 (Farber, 1956), oval cells
have been extensively characterized histologically, which cumu-
latively suggests that they have bipotential differentiation
capability toward both hepatocytes and cholangiocytes. Unfor-
tunately, the lack of genetic lineage tracing systems in rats (as
well as the absence of oval-cell-specific markers) has hindered
efforts to verify this theory. It is thus quite natural for liver biolo-
gists to examine whether oval cells exhibit stem cell activity in
mouse models. Although the 2-AAF/PHx system is not appli-
cable in mice, several other liver injury models have been used
for ‘‘oval cell’’ induction, among which the administration of
a 3,5-diethoxycarbonyl-1,4-dihidro-collidine (DDC)-containing
diet (Preisegger et al., 1999) or a choline-deficient ethionine-sup-
plemented diet (CDE) (Akhurst et al., 2001) are the most exten-
sively used. However, it seems that the blockade of hepatocyte
proliferation in these mouse models is not as complete as in the
rat 2-AAF/PHx model. Moreover, the injuries sustained in those
mouse models are markedly different from that of the 2-AAF/
PHx rat model. The DDC-induced injury is considered to be tar-
geted primarily to the biliary compartment and serves as amodel
for sclerosing cholangitis and biliary fibrosis (Fickert et al., 2007),
while the CDE protocol induces fatty liver and is sometimes used
as a model for nonalcoholic steatohepatitis. As the phenotypic
and mechanistic differences among these models as well as
other ‘‘oval cell’’ induction protocols have become more and
more recognized, there is an increasing consensus that the cells
induced therein are not exactly the same. Thus, applying the ter-
minology ‘‘oval cell’’ in mouse injury models seems to have
caused substantial confusion and should be avoided. We sug-
gest that ‘‘LPC’’ (liver progenitor cell) is a more appropriate
term to broadly describe all the various disease-activated, puta-
tive stem/progenitor cell populations that have been observed in
the liver regardless of species or injury model.
Characterization of LPCs by Molecular Markers
Despite their potentially different characteristics and ontogeny
based on disease etiology, various common markers, such as
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LPCs in mice, rats, and humans (Okabe et al., 2009; Rountree
et al., 2007; Suzuki et al., 2008; Yovchev et al., 2007). Sox9,
osteopontin, and the MIC1-1C3 antigen are also regarded as
equivalent LPC markers, at least in mice (Carpentier et al.,
2011; Dorrell et al., 2008, 2011; Matsuo et al., 2011). Using
flow-cytometry-based cell separation methods in conjunction
with cell surface markers (e.g., EpCAM, CD133, or MIC1-1C3)
or fluorescent reporters (e.g., Sox9-dependent YFP reporter),
LPCs can be viably isolated and subjected to in vitro culture to
be evaluated for their proliferation and differentiation potentials.
Collectively, such isolation and culture methods have demon-
strated that LPCs contained cells that are clonogenic in vitro
and can differentiate into both hepatocytic and cholangiocytic
lineages under certain culture conditions (Table 2 and Figure 3).
These results strongly suggest that LPCs, when strictly defined
by clonogenicity and in vitro differentiation potential, indeed
contain bipotential stem/progenitor cells in the liver. Importantly,
cholangiocytes isolated from the normal liver based on the same
molecular markers also qualitatively exhibit the same potential
in vitro. Thus, it remains uncertain whether in vitro assays
adequately and specifically evaluate the potential of disease-
activated LPCs distinct from the ‘‘potential’’ liver stem cells
residing in the biliary compartment under normal conditions.
Several studies have identified possible LPC-specific markers
that can distinguish LPCs form cholangiocytes in the normal
liver. Trop2 (Tacstd2), a transmembrane molecule that is struc-
turally related to and is a paralog of EpCAM, has been found to
be expressed exclusively in LPCs under the DDC-induced injury
condition, but not in cholangiocytes in the normal liver (Okabe
et al., 2009). Thus, Trop2 may serve as a genuine LPC-specific
marker and if so, it would be advantageous for further character-
ization of LPCs. The clonogenicity and differentiation potential of
the Trop2+ cells as well as experiments tracing their fate have not
yet been examined. The transcription factor Foxl1 has been
identified as another potential LPC-specific marker, in that a
transgenic (Tg) mouse line expressing Cre recombinase under
the control of the Foxl1 promoter has been used to demonstrate
that both hepatocytes and cholangiocytes were derived from
Foxl1+ LPCs under certain injury conditions (Sackett et al.,
2009). The Cre recombinase used in the Foxl1-Cre Tg mouse is
constitutively expressed and cannot be temporally regulated,
so it remains undetermined whether single Foxl1+ LPCs can
clonally differentiate into these two lineages or whether the
Foxl1+ population contains distinct hepatocytic and cholangio-
cytic progenitors. More recently, Lgr5, a well-establishedmarker
for stem cells in the intestine as well as several other tissues/
organs, has also been demonstrated to be expressed specif-
ically in damage-induced LPCs in the liver using Lgr5-LacZ
and Lgr5-CreERT2 KI mice (Huch et al., 2013). Lgr5+ cells can
be clonally expanded as transplantable organoids in a 3D culture
system, and those organoids retain many characteristics of the
original epithelial architecture. The relationship between Lgr5+
cells and those expressing the authentic LPC markers such as
CK19 and EpCAM has not been clearly determined. In addition,
a major drawback for Foxl1 and Lgr5 is that expression of the
endogenous genes/proteins in LPCs has not been clearly
demonstrated thus far, and assays currently rely on the use of
those particular Tg and KI mouse lines. It should be emphasizedthat the Foxl1 and Lgr5 markers are not expressed prior to
damage and thus cannot be used to prelabel the cells that arise
during regeneration. Nevertheless, further characterization of
such cell populations should provide unique and more versatile
LPC-specific markers and genetic tools, with which clonal ana-
lyses of LPCs may be achieved in vivo.
Origin of LPCs
LPCs are apparently a ‘‘facultative’’ stem/progenitor cell popula-
tion that emerge and are recognized only under damage condi-
tions, and the cell of origin for this subset of cells is of significant
interest. Based on the histological analyses of rat oval cells, it has
long been proposed that the canal of Hering, the junctional struc-
ture connecting bile canaliculi formed by hepatocytes with bile
ducts lined by cholangiocytes, is the origin of these cells (Paku
et al., 2001) (Figure 3). This notion is consistent with the fact
that LPCs almost always emerge from the periportal area.
Furthermore, given its anatomical location between cholangio-
cyte and hepatocyte populations, it seems reasonable to
assume that this structure may serve as a niche for putative
progenitor cell populations that are destined to differentiate
toward these two cell lineages. Hence, the concept that the
canal of Hering may serve as the origin of LPCs is widely
accepted, though it is not formally proven to be applicable to
such progenitors in general. This notion further suggests that
the canal of Hering serves as a niche for a specialized precursor
cell population for LPCs, which some researchers would prefer
to denote as ‘‘liver stem cells.’’ Unfortunately, however, direct
proof for this idea is still hampered by lack of any specific marker
for such cells as well as the cells constituting the canal of Hering.
As mentioned earlier, in vitro assays have clearly detected the
presence of potential liver stem cells with clonogenicity and
bilineage differentiation potential in the biliary compartment,
even in the normal liver. It is of considerable interest to determine
whether they actually correspond to and play a role as the
reserve stem cells in vivo to produce LPCs once the liver is
injured.
While much effort is still underway to identify putative, specific
markers for the cell of origin for LPCs, Cre/loxP-mediated ge-
netic lineage tracing studies in mice have been done by labeling
‘‘mature’’ liver epithelial cells based on well-established differen-
tiation markers. Consistent with the fact that most of the molec-
ular markers for LPCs are also expressed in cholangiocytes,
lineage tracing studies employing cholangiocyte-specific Cre
driver strains have collectively indicated that LPCs identified
under liver injury conditions can be derived from cholangiocytes
in the normal liver (Dorrell et al., 2011; Espan˜ol-Sun˜er et al., 2012;
Furuyama et al., 2011). It is not clear, however, whether most if
not all cholangiocytes can equally or similarly behave as precur-
sors for LPCs, or if there is a certain type of specialized ‘‘LPC
cell-of-origin’’ subpopulation located somewhere among chol-
angiocytes. For the latter possibility, the cholangiocytes adja-
cent to hepatocytes that form the canal of Hering would be a
plausible candidate. Notably, the potential contribution of hepa-
tocytes as an origin for LPCs can also be considered. In a study
using mice with chimeric livers generated from the transplanta-
tion of wild-type (Fah+/+) mouse-derived hepatocytes to Fah/
recipients, which resulted in more than 90% repopulation,
almost all of the LPCs induced upon subsequent application ofCell Stem Cell 14, May 1, 2014 ª2014 Elsevier Inc. 569
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derived from repopulated (wild-type) hepatocytes, suggesting
that hepatocytes are not likely to act as the cell of origin for
LPCs (Wang et al., 2003). However, more recent studies employ-
ing lineage tracing approaches have demonstrated that hepato-
cytes can be reprogrammed to LPCs under certain liver injury
conditions including the DDC model (Yanger et al., 2013). Again,
it is unclear whether most if not all mature hepatocytes possess
such plasticity or whether there are specific subsets of hepato-
cytes, such as those lining a part of the canal of Hering, that
can be converted to LPCs.
In addition to the phenotypic and ontogenic characterization
of LPCs, many recent studies focus on elucidating the cellular
and molecular frameworks for their regulatory mechanisms
and have identified several key signaling pathways. Similar to
the various extrahepatic tissue stem/progenitor cells, a set of
developmental ‘‘toolkit’’ genes, including Wnt (Apte et al.,
2008; Boulter et al., 2012; Hu et al., 2007; Itoh et al., 2009;
Yang et al., 2008), Notch (Boulter et al., 2012; Fiorotto et al.,
2013; Kitade et al., 2013), and FGF (Takase et al., 2013), have
been shown to play a relevant role in LPC regulation. Consistent
with the notion that chronic liver injury conditions where LPCs
are activated usually accompany inflammatory responses,
involvement of several inflammatory cytokines, such as tumor
necrosis factor (TNF)-alpha, interleukin-6, and interferon-
gamma, has also been reported (Akhurst et al., 2005; Knight
et al., 2000; Yeoh et al., 2007). Among those factors, TNF-related
WEAK inducer of apoptosis (TWEAK) and FGF7 are of particular
interest because they are capable of inducing de novo activation
of LPCs. Forced expression of either of these factors in the
normal liver can lead to induction and expansion of cells reminis-
cent of LPCs, even in the absence of any liver injury regimen
(Jakubowski et al., 2005; Takase et al., 2013). This phenomenon
strongly suggests that the cell of origin for LPCs is responsive to
these extracellular signals. Other growth factors, such as HGF
and EGF, have also been implicated in regulating proliferation
and/or differentiation of LPCs (Ishikawa et al., 2012; Kitade
et al., 2013). These humoral factors may be of potential use in
therapeutic strategies to counter liver disease by enhancing
the inherent regenerative capacity within the organ.
Cancer Stem Cells in the Liver and Their Origins
Tumors exhibit considerable heterogeneity even though they
arise clonally. This heterogeneity is thought to result from hierar-
chical organization of the tumor cells by a subset of cells with
stem cell features, i.e., cancer stem cells (CSCs) with the poten-
tial for self-renewal and differentiation (Kreso and Dick, 2014).
Because elimination of CSCs is necessary for eradication of tu-
mors, much attention has been given to the identification of
CSCs for developing effective therapeutic drugs. Besides such
a practical point of view, the origin of CSCs, an abnormal stem
cell type, is of considerable interest in stem cell biology. Liver
cancer is an aggressive disease with a poor outcome. Among
primary liver cancers, hepatocellular carcinoma (HCC) accounts
for 70%–85% of the cases and intrahepatic cholangiocarcinoma
(ICC) is the second most frequent type of liver cancer. Both HCC
and ICC are heterogenous in their cellular morphology and clin-
ical outcome. Mixed HCC-cholangiocellular carcinoma (HCC-
CCC) is a rare form of liver cancer exhibiting both hepatocellular570 Cell Stem Cell 14, May 1, 2014 ª2014 Elsevier Inc.and cholangiocellular features, reminiscent of liver stem/progen-
itor cells. Intriguingly, forced expression of polycomb group pro-
tein Bmi1 or b-catenin in hepatoblasts allowed their expansion
in vitro, and transplantation of clonally expanded cells produced
tumors with histological features of combined HCC-CCC, sug-
gesting that liver stem/progenitor cells may be the origin of
such tumors (Chiba et al., 2007). However, the vast majority of
human HCCs arise from chronic infection with hepatitis virus
with HCC subsequently developing after a long latency, suggest-
ing that HCC is derived from mature hepatocytes. HCC exhibits
considerable heterogeneity and often contains cells expressing
liver stem/progenitor markers, e.g., EpCAM, CD133, CD44,
CD24, and DLK1 (reviewed in Yamashita and Wang, 2013).
Consistently, recent studies have identified the oncofetal gene
SALL4, which encodes a transcription factor functioning in fetal
liver development (Oikawa et al., 2009), as a prognostic marker
for a progenitor subclass of hepatocellular carcinoma with an
aggressive phenotype (Oikawa et al., 2013; Yong et al., 2013;
Zeng et al., 2014). Interestingly, some cell lines derived from
HCC such as Huh7 also show heterogeneity and a subpopula-
tion expressing some of these stem/progenitor cell markers or
excreting Hoechst dye (side population) were shown to develop
tumors in immunodeficient mice, indicating that they are tumor
initiating cells, a key characteristic of CSCs (Chiba et al., 2006;
Haraguchi et al., 2010). However, because most of previous
studies showing tumor-initiating activity were based on cell lines,
isolation of fresh cells with stem cell markers from patient tissues
and demonstration of tumor-initiating activity is necessary for
precise identification of liver CSCs. Because stem/progenitor
cell markers are often expressed in HCC, mature hepatocytes
may regress to an immature stage during tumorigenesis. Alterna-
tively, there may be immature hepatocytes infected with virus,
which then give rise to tumors. Intriguingly, recent studies using
cell fate tracing of hepatocytes demonstrated that ICC originates
from hepatocytes rather than cholangiocytes and that Notch and
Akt signaling cooperate to convert hepatocytes into biliary cells
that act as precursors of ICCs (Fan et al., 2012; Sekiya and
Suzuki, 2012). While it remains unknown whether stem/progen-
itor cells emerge transiently during the conversion, the plasticity
of hepatocytes provides insight into the mechanism for patho-
genesis as a consequence of defective liver regeneration.
Conclusion
Hepatocytes and cholangiocytes are two types of liver epithelial
cells and the cell type that eventually gives rise to both epithelial
cells has been considered to be the liver stem cell. In fetal, adult,
and diseased livers, there are clearly some cells with the poten-
tial to proliferate and differentiate to both cell types in vitro, indi-
cating the presence of ‘‘potential’’ stem cells in liver. However, if
the liver stem cell is defined by the ability for continuous self-
renewal and contribution to both type of epithelial cells in vivo,
it is questionable whether liver stem cells are present in the
body. Hepatoblasts in fetal liver proliferate but also change their
phenotype throughout development, so they are more appropri-
ately defined as progenitor cells. In normal adult liver, the pres-
ence of a resident self-renewable stem cell still remains to be
demonstrated. In injured and regenerating livers, proliferating
cells around the portal vein are also better referred to as progen-
itor cells rather than stem cells until any solid evidence showing
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cytes in vivo is provided. Because there is substantial variability
among definitions and identification strategies, extreme caution
and consideration should be employed when comparing results
from the literature that refer to ‘‘liver stem cells,’’ as the charac-
teristics of these cells may vary according to the way they are
defined in each study.
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